OEP News
Press Release 08 Nov. 2022
Preventive Voluntary Recall for Ectrin Capsule 300mg (Update)
MORE
Press Release 25 Oct. 2022
Orient EuroPharma Introduces Novel injectable treatments Manufactured by Chiesi for the Treatment of Rare Diseases, Offering New Therapeutic Options of Enzyme Replacement Therapy to Patients in Taiwan and Southeast Asia Markets
MORE
Press Release 22 Sep. 2022
Taiwan Is Facing Obesity Crisis; the Latest Mechanistically Modified Oral Obesity Drug Is Available for Prescription
MORE
Explore OEP
About OEP
Built on understanding and meeting the real needs of people,
OEP is aim to become a benchmark enterprise in the Asia Pacific
Careers
Sincerely invite you to join OEP
Business Development
Continues to introduce a diverse range of innovative products and
expanding its overseas markets
Investors
Monthly Revenues 2022 October
CSR
OEP hopes to create a better society through continuous efforts and innovation
OEP Subsidiaries
Orient PHARMA, OP NanoPharma &
OEP Innovations
Overseas Business
To follow the trend of internationalization, Orient EuroPharma started to expand the foreign market in 1993 by establishing subsidiaries in Southeast Asia and moved into the Mainland China market with a complete marketing network.
